Ephedra Safety Studies Urged By Burton In Letter To FDA
This article was originally published in The Tan Sheet
Executive Summary
FDA should "support clinical trials that will examine scientifically the safety of ephedra when properly used," Rep. Dan Burton (R-Ind.) states in a May 19 letter to the agency
You may also be interested in...
Ephedra “Black Box” Warning Considered By FDA
FDA is suggesting that a "black box" warning appear on the principal display panel of all ephedrine alkaloid-containing dietary supplements, FDA Commissioner Mark McClellan, MD/PhD, said during a Feb. 28 briefing held in Washington, D.C
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands